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Abstract
Background: Sepsis has several clinical stages, and mortality rates are different for each stage. Our goal was to
establish the evolution and the determinants of the progression of clinical stages, from infection to septic shock,
over the first week, as well as their relationship to 7-day and 28-day mortality.
Methods: This is a secondary analysis of a multicenter cohort of inpatients hospitalized in general wards or
intensive care units (ICUs). The general estimating equations (GEE) model was used to estimate the risk of
progression and the determinants of stages of infection over the first week. Cox regression with time-dependent
covariates and fixed covariates was used to determine the factors related with 7-day and 28-day mortality,
respectively.
Results: In 2681 patients we show that progression to severe sepsis and septic shock increases with intraabdominal
and respiratory sources of infection [OR = 1,32; 95%IC = 1,20-1,46 and OR = 1.21, 95%CI = 1,11-1,33 respectively], as
well as according to Acute Physiology and Chronic Health Evaluation II (APACHE II) [OR = 1,03; 95%CI = 1,02-1,03]
and Sequential Organ Failure Assessment (SOFA) [OR = 1,16; 95%CI = 1,14-1,17] scores. The variables related with
first-week mortality were progression to severe sepsis [HR = 2,13; 95%CI = 1,13-4,03] and septic shock [HR = 3,00;
95%CI = 1,50-5.98], respiratory source of infection [HR = 1,76; 95%IC = 1,12-2,77], APACHE II [HR = 1,07;
95% CI = 1,04-1,10] and SOFA [HR = 1,09; 95%IC = 1,04-1,15] scores.
Conclusions: Intraabdominal and respiratory sources of infection, independently of SOFA and APACHE II scores,
increase the risk of clinical progression to more severe stages of sepsis; and these factors, together with progression
of the infection itself, are the main determinants of 7-day and 28-day mortality.
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Background
Infection is the pathologic phenomenon induced by
microorganisms, and sepsis is the systemic response to
infection. Severe sepsis occurs when organ dysfunction
appears, and septic shock is a sustained reduction of ar-
terial blood pressure that impairs adequate tissue perfu-
sion [1,2]. In previous years, the diagnosis and treatment
of sepsis appeared chaotic, partly because of a lack of uni-
form terminology [1,3]. Consequently, one of the most im-
portant advancements was the ACCP/SCCM consensus,
which unified the criteria and definitions for diagnosing the
syndrome [1]. The process has traditionally been under-
stood as a linear sequence spanning different clinical stages
[4], from infection to septic shock. However, with few ex-
ceptions such a clinical trial carried out almost two decades
ago [5], some theoretical models with mathematical simula-
tions [6,7], and cohort studies with highly selected patients,
whether by ICU admission [8] or by the specific diagnosis
of pneumonia [9]; a formal and adequate characterization
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of the potential progression from infection without
systemic manifestations to septic shock or death has
not been attempted. To understand this clinical behavior,
and to know the timeline and the timing of relevant events
within the sepsis syndrome, might be a cornerstone of the
real dynamic behind infection and host’s response.
In Colombia, we have found some particular features
that suggest differences in the natural history and clinical
course of bacterial infections with regard to other places in
the world [10,11]. Under these circumstances, which are
probably valid for most of the third world, complete clinical
characterization of that potential progression may make it
possible to propose more effective strategies to face the
problem. This would be especially valuable for reducing
mortality, which varies with the clinical stages: in patients
with infection without sepsis, with sepsis, with severe
sepsis, and with septic shock, the mortality rates are
3%, 7,3%, 21,9%, and 45,6%, respectively [11]. The aim
of this research is to describe the evolution of the stages of
sepsis in a multicenter cohort of patients with bacterial
infections requiring hospitalization. The study also aims to
identify the determinants of the progression of these stages,
as well as their relationship with 7 and 28-day mortality.
Methods
Settings and study design
This is a secondary analysis of the study The Epidemiology
of Sepsis in Colombia [11], which is a prospective
multicenter cohort study with patients admitted to ten
hospitals in the four main cities of Colombia from
September 1, 2007, to February 29, 2008. We included
patients from emergency rooms, ICUs, and hospital
wards covering both community- and hospital-acquired
infections. Patients were considered eligible if they
were 18 years or older; had a probable or confirmed
diagnosis of infection according to medical records; or
had changes in temperature (>38 or <36°C) or hypotension
without a specific cause. Furthermore, as definitive in-
clusion criterion, patients must have had an infection
that fulfilled standard Centers for Disease Control and
Prevention definitions [12]. Patients were excluded if
they refused to participate, were screened for eligibility
≥ 24 hrs after suspicion of infection, stayed 48 hrs in
another institution immediately before the current
hospitalization, were not available for 28-day follow-up
, were discharged < 24 hrs after hospitalization, their
diagnosis changed toward a noninfectious disease dur-
ing hospitalization, or were previously recruited in the
study. Hospital-acquired infections were defined as
those not present or incubating at the time of admis-
sion to the hospital, i.e., infections that become evident
48 hrs after admission. The study protocol was approved
by the ethical committee of the Medical Research Center
(University of Antioquia). Oral informed consent was
obtained in all hospitals except in two in which written
informed consent was requested.
Data collection, evaluation, and quality control
There were one or two trained nurses, according to the
number of beds, in each hospital. They followed a study
protocol standardized twice in 2-day workshops devel-
oped within a 3-month pilot study, which was conducted
immediately before starting the recruitment. In each
hospital, there was also a clinician coinvestigator who
was in charge of checking data accuracy and consistency
as well as the patient’s diagnosis. In addition, the case
report forms were checked and revised weekly in a
double-entry form in the Data Coordinating Center
(Universidad de Antioquia). Any inconsistency, inaccuracy,
or missing data implied returning the specific case report
form to the coinvestigator for correction within the next
week after the Data Coordinating Center review. There was
also on site evaluation during the first month of the study
at each hospital by one of the coprincipal investigators. At
the recruiting areas of the hospitals, all the inpatients were
actively screened for the presence of infection. The severity
of illness was assessed using the Acute Physiologic and
Chronic Health Evaluation II score [13], and the frequency
and magnitude of organ dysfunction was measured with
the Sequential Organ Failure Assessment score [14], both
determined within the first 24 hrs after enrollment of the
patient. We recorded also demographic characteristics, first
admission diagnosis, comorbidities and clinical status
as infection, sepsis, severe sepsis or septic shock daily
during the first seven days (Additional file 1). For this
clinical status classification, those laboratory tests not re-
quested were considered as normal. For patients discharged
before 28 days, their vital status was confirmed by tele-
phone call or outpatient control.
Study outcomes
Primary outcomes: clinical progression from infection to
sepsis, severe sepsis or septic shock and 7-days mortality.
Secondary outcome: 28-days mortality.
Statistical analysis
Categorical and ordinal variables were expressed as pro-
portions; continuous variables as means with standard
deviations or medians with interquartile ranges, according
to data distribution. In order to identify the determinants
of progression across different clinical stages of sepsis,
it is necessary to consider a longitudinal data analysis.
Longitudinal data analyses come from studies in which
the outcome variable is measured on the same individual
at several occasions (e.g., daily clinical stage) and, conse-
quently, observations are not independent of each other.
With the method of General Estimating Equations (GEE),
the correction for the dependency of observations is
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done by assuming a correlation structure for the re-
peated measurements of the outcome variable. These
correlation structures vary from an interchangeable
(i.e., the correlations between subsequent measurements
are assumed to be the same) to an unstructured one
(i.e., no particular correlation shape is assumed and all
possible correlations between repeated measurements has
to be estimated) [15]. Therefore, we estimated the odds of
progression of clinical stages with a general estimating
equations (GEE) model for a binomial distribution, as-
suming an interchangeable correlation between mea-
sures and a robust (Huber-White) estimator of variance
[16,17]. The outcome variable was the daily progression of
the clinical condition over the first week (infection without
sepsis, sepsis, severe sepsis, septic shock, and death);
and we regarded as independent variables those which,
as the literature suggests, are potentially related to that
progression [8,18,19]: age; sex; place of acquisition of
infection; source of infection; comorbidities (at least
one of the following: HIV/AIDS, trauma or surgery
during the past 30 days, congestive heart failure, organ
transplantation, cirrhosis, use of steroids or chemotherapy
during the last year, drug addiction or alcoholism, chronic
obstructive pulmonary disease, chronic renal failure and/
or dialysis, diabetes mellitus, or history of cancer during
the past year); SOFA and APACHE II scores; and type of
microorganism identified in blood.
As supported by the GEE model, we assumed a constant
odds of progression both among stages and within days,
and we also considered that the data were missing com-
pletely at random. As a sensitivity analysis, the model was
fitted with deaths during the first week considered both as
missing data and also as a fifth stage, without significant
changes in the results. On the other hand, in the literature
it is supported that GEE analysis is robust against a wrong
choice for a correlation structure. It means that it does
not matter which correlation structure is chosen, the
results of the longitudinal analysis will be more or less the
same [20,21]. However, as a sensitivity analysis, we fitted
GEE models also assuming either an unstructured or an
“independent” correlation structure, without significant
changes in the results.
Cox regression analysis was used to determine the
effect of clinical progression from one stage to another
(time-dependent covariate) on first-week mortality, adjusted
for fixed variables such as age, sex, place of acquisition
of infection, source of infection, comorbidities, SOFA,
APACHE II, and type of microorganism identified in
blood. These results were verified with a Cox model for
28-day mortality with the clinical stages on the first day
as fixed variables. Patients discharged alive from hospital
were considered censored, and the proportional-hazards
assumption was verified by the Schoenfeld residuals test,
as well as all potential interactions between variables [22].
All measures of association, OR and HR, were accom-
panied by their corresponding 95% confidence intervals;
all statistical analyses were performed with STATA 12.1
(Stata Corp. College Station, TX, USA).
Results
Of the 2681 patients enrolled, 136 (5.1%) were classified
as having infection without sepsis, 575 (21.4%) with sepsis,
1576 (58.8%) with severe sepsis, and 394 (14.7%) with septic
shock at the moment of inclusion in the study. The mean
age was 55 yrs (SD = 21 yrs), 1365 (51%) were female, the
mean Acute Physiologic and Chronic Health Evaluation II
(APACHE II) score was 11.5 (SD = 7), and the mean
Sequential Organ Failure Assessment (SOFA) score was 3,8
(SD = 3). The most common associated conditions were
trauma or surgery in 28,5% (n = 764), diabetes mellitus in
15,2% (n = 408), chronic renal disease in 10,5% (n = 281),
heart failure in 9,9% (n = 266), and chronic obstructive
pulmonary disease in 9,9% (n = 265). Among the total
cohort, 879 patients (33%) did not have any comorbidity.
The overall 7-day and 28-day mortality rate was 9.2%
(n = 247) and 18.5% (n = 497), respectively.
Considering the clinical stage at the moment of inclusion,
the mean age was 48,5 years (SD = 20,4) for the group of
patients with infection without sepsis, and 57,2 years
(SD = 20,2) for the septic shock group. In the first group,
community-acquired infection accounted for 73,5% of
cases, with infection of the urinary tract as the most fre-
quent diagnosis in 31%, followed by soft-tissue infection
with 29%; as opposite to the septic shock group, in
which pneumonia was the most common infection with
29,4% of cases, followed by intraabdominal infection in
16.5% of patients (Table 1). More than half of the pa-
tients at all clinical stages had at least one comorbidity,
with trauma or surgery as the most frequent. SOFA and
APACHE scores, as well as the median length of hospital
stay and 28-day mortality, increased proportionally with
the progression of the clinical stages (Table 1). From day 1
to 2, the proportion of patients with infection without sep-
sis increased from 5% to 21% and the proportion of septic
patients increased from 21% to 34%, whereas the propor-
tion of patients with severe sepsis decreased from 59% to
32%. The frequency of septic shock did not change sub-
stantially, and maintained a similar distribution over the
first week. Likewise, the proportion of discharges due to
death reduced daily over the first week. It is noteworthy
that most deaths during that period of time occurred at
stages of severe sepsis and septic shock (Figure 1).
Risk of progression
The adjusted GEE model showed a 9% reduction of the
odds of progression over the first week to more severe
clinical stages in patients with skin and soft tissues
infections, compared with those with urinary infection
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Figure 1 Distribution of patients according to stages of infection (infection without sepsis [I], sepsis [S], severe sepsis [SS], and septic
shock [Sx]) for each day of follow-up.
Table 1 General characteristics of study population according to initial clinical stage
Characteristics
Infection without sepsis Sepsis Severe sepsis Shock
(n = 136) (n = 575) (n = 1576) (n = 394)
Age* 48.5 ± 20.4 49.3 ± 20.5 57.3 ± 20.1 57.2 ± 20.2
Male sex† 70 (51.5) 258 (44.9) 789 (50.1) 199 (50.5)
Community-acquired infection† 100 (73.5) 377 (65.6) 1120 (71.1) 249 (63.2)
Urinary tract infection† 42 (31.0) 120 (20.9) 369 (23.4) 40 (10)
Pneumonia† 9 (6.6) 101 (17.6) 417 (26.4) 116 (29.4)
Intra-abdominal infection† 4 (2.9) 27 (4.7) 161 (10.2) 65 (16.5)
Skin and soft tissues† 40 (29) 116 (20) 183 (11.6) 35 (8)
Trauma or surgery† 42 (30.9) 176 (30.6) 396 (25.1) 150 (38.1)
No comorbidities† 67 (49.3) 210 (36.5) 510 (32.4) 92 (23.4)
SOFA* 0.6 ± 0.8 1.2 ± 1.2 3.9 ± 2.4 8.0 ± 3.5
APACHE II* 4.4 ± 3.7 7.3 ± 4.9 12.4 ± 6.2 17.3 ± 6.7
Hospital stay‡ 5 (2 – 39) 8 (1 – 77) 10 (1 – 79) 12 (1 – 74)
28-day mortality† 3 (2.2) 47 (8.2) 276 (17.6) 172 (43.6)
* Mean and standard deviation †Absolute frequency and percentage ‡Median and interquartile range.
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(OR = 0,91; 95% CI = 0,84-1,00); whereas intraabdominal
infection increased the odds by 32% with regard to the
same comparison group (OR = 1,32; 95% CI = 1,20-1,46).
Other determinants of the odds of progression to more
severe stages over the first week were the initial SOFA and
APACHE II scores (OR = 1,16 [95% CI = 1,14-1,17] and OR
1,03 [95% CI = 1,02-1,03] for each point of increase,
respectively), as well as respiratory infections and other
sources of infection (Table 2). On univariate analysis,
age (OR = 1.00; 95% CI = 1–1,01 by each year), male sex
(OR = 1,07; 95% CI = 1-1,15), comorbidities (OR = 1,30;
95% CI = 1,21-1,40), and identification of Gram-negative
microorganisms in blood (OR = 1,58; 95% CI = 1,41-1,75),
among others, also seemed to increase the risk of progres-
sion, but such associations disappeared after adjustment
for other covariables (Table 2).
Risk of 7-day and 28-day mortality
The adjusted analysis of mortality during the first week
with time-dependent covariates confirmed that the progres-
sion to severe sepsis and septic shock significantly increased
the hazard of death: HR = 2,13; 95% CI = 1,13-4,03 and
HR = 3,00; 95% CI = 1,5-5,98, respectively. Other inde-
pendent determinants of mortality were age, respiratory
source of infection, and initial SOFA and APACHE scores
(Table 3). When verifying these findings with the outcome
of 28-day mortality and clinical stages of infection as fixed
variables at the moment of inclusion, only septic shock
was significantly associated with mortality (HR = 2.10; 95%
CI = 1,33-3,32). The risk of 28-day mortality was also asso-
ciated with hospital-acquired infection, intraabdominal
and other infection sources besides respiratory, age, and
SOFA and APACHE scores (Table 4).
Discussion
Our analysis showed that progression from infection to
sepsis, severe sepsis or septic shock is strongly determined
by the source of infection, independent of the initial values
of SOFA and APACHE II scores. Similarly, this progression
between clinical stages jointly with severity scores, age and
the respiratory source of infection were the main determi-
nants of mortality during the first week. We use specialized
statistical models in order to fully explore the timeline
of progression of the clinical stages of sepsis. Previously,
Table 2 Univariate and multivariate GEE models for estimating determinants of progression to sepsis, severe sepsis, or
septic shock during the first week of hospital stay
Covariables
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Age (for each year of increase) 1.00 (1.00 – 1.01) <0.001 1.00 (1.00 – 1.00) 0.445
Sex
Female 1 Reference 1 Reference
Male 1.07 (1.00 – 1.15) 0.037 0.97 (0.92 – 1.02) 0.236
Site
Community 1 Reference 1 Reference
Hospital 1.12 (1.04 – 1.20) 0.002 1.03 (0.96 – 1.09) 0.409
Source of infection
Urinary 1 Reference 1 Reference
Respiratory 1.53 (1.38 – 1.68) <0.001 1.21 (1.11 – 1.33) <0.001
Skin and soft tissues 0.81 (0.73 – 0.91) <0.001 0.91 (0.84 – 1.00) 0.041
Intra-abdominal 1.64 (1.46 – 1.84) <0.001 1.32 (1.20 – 1.46) <0.001
Other infections 1.33 (1.22 – 1.44) <0.001 1.16 (1.08 – 1.25) <0.001
Comorbidities
Without comorbidities 1 Reference 1 Reference
With any comorbidity 1.30 (1.21 – 1.40) <0.001 1.01 (0.95 – 1.07) 0.774
SOFA score (0 – 24, for each unit of increase) 1.21 (1.20 – 1.22) <0.001 1.16 (1.14 – 1.17) <0.001
APACHE II score (0 – 67, for each unit of increase) 1.08 (1.07 – 1.08) <0.001 1.02 (1.02 – 1.03) <0.001
Blood cultures
Not requested 1 Reference 1 Reference
Negative 1.17 (1.09 – 1.27) <0.001 0.96 (0.91 – 1.03) 0.281
Gram-positive bacteria 1.46 (1.28 – 1.66) <0.001 0.99 (0.88 – 1.11) 0.867
Gram-negative bacteria 1.58 (1.41 – 1.75) <0.001 1.01 (0.93 – 1.11) 0.748
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Clermont et al. worked on dynamic microsimulation
models to predict the temporal patterns of multiple
outcomes in critically ill patients [23]. However, such
approaches address mainly issues of prediction and
forecasting and are not suitable enough for identification
of individual covariates.
On the other hand, it has been reported in the literature
that mortality has differential behavior according to the
complexity and the source of the infection; with mortality
rates usually higher at the stages of severe sepsis and
septic shock, as well as in patients with pneumonia
[1,3,5,8,24-27]. Our results confirm that septic shock as
initial clinical stage, in addition to several sources of in-
fection, increases the 28-day hazard of death. However,
when stage shifts over the first week are assessed, it is
clear that progression to severe sepsis and/or to septic
shock are also independent determinants of mortality
and the respiratory source of infection remained as a
significant prognostic factor.
In order to compare our findings with those of other
investigations, it is necessary to take into account all the
differences of our study population. Our cohort consists
of patients with community- and hospital-acquired infec-
tions, hospitalized in ICU or in general wards, whose mean
age shows a young population, 33% of whose individuals
have no comorbidities. In terms of the quantification of
severity by SOFA and APACHE II scores, our data are
comparatively low in comparison with those of other
populations, even in the septic shock group [7-9,28-30].
Alberti et al. [8] published a multicenter study that
enrolled 3443 ICU patients diagnosed with infection,
1531 of whom did not present with severe sepsis or
shock. Eleven percent (n = 167) and 13% (n = 201) of
these patients progressed to severe sepsis and septic
Table 3 Univariate and multivariate Cox models for 7-day mortality with clinical stage as time-dependent covariate
Covariables
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (for each year of increase) 1.02 1.01 – 1.02 <0.001 1.01 1.00 – 101 0.039
Sex
Female 1 Reference 1 Reference
Male 1.02 0.81 – 1.27 0.875 0.98 0.76 – 1.27 0.899
Site
Community 1 Reference 1 Reference
Hospital 1.29 1.02 – 1.62 0.034 1.33 0.98 – 1.80 0.064
Source of infection
Urinary 1 Reference 1 Reference
Respiratory 2.70 1.85 – 3.95 <0.001 1.76 1.12 – 2.77 0.014
Skin and soft tissues 1.07 0.68 – 1.69 0.776 1.22 0.73 – 2.02 0.441
Intra-abdominal 2.36 1.52 – 3.65 <0.001 1.50 0.90 – 2.48 0.118
Other infections 2.34 1.65 – 3.31 <0.001 1.89 1.28 – 2.80 0.001
Comorbidities
Without comorbidities 1 Reference 1 Reference
With any comorbidity 1.52 1.17 – 1.98 0.002 0.88 0.65 – 1.20 0.426
SOFA score (0 – 24, for each unit of increase) 1.24 1.21 – 1.27 <0.001 1.09 1.04 – 1.15 0.001
APACHE II score (0 – 67, for each unit of increase) 1.13 1.11 – 1.14 <0.001 1.07 1.04 – 1.10 <0.001
Blood cultures
Not requested 1 Reference 1 Reference
Negative 1.07 0.82 – 1.40 0.603 0.91 0.67 – 1.23 0.546
Gram-positive bacteria 1.37 0.88 – 2.11 0.158 0.83 0.50 – 1.36 0.454
Gram-negative bacteria 1.04 0.68 – 1.58 0.858 0.59 0.36 – 0.95 0.031
Classification of infection (progression to)
Infection without sepsis 1 Reference 1 Reference
Sepsis 2.75 1.47 – 5.15 0.002 1.76 0.93 – 3.33 0.081
Severe sepsis 4.95 2.71 – 9.06 <0.001 2.13 1.13 – 4.03 0.019
Septic shock 13.51 7.41 – 24.64 <0.001 3.00 1.50 – 5.98 0.002
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shock, respectively, at some moment of their ICU stay
before day 30. One of the chief factors of that progres-
sion to severe sepsis or septic shock was the source of
infection; the risk was highest in cases of bacteremia
(HR = 1,81; 95% CI =1,18-2,76), followed by peritonitis
(HR = 1,51; 95% CI = 1,07-2,13) and pneumonia (HR = 1,47;
95% CI = 1,18-1,82). These results are in keeping with
our own. Besides including only ICU patients and not
estimating the effect of clinical progression on mortal-
ity, that study carried out an analysis based only on the
time elapsed between admission and the appearance of
severe sepsis or septic shock using a Cox model with
competing risks. Such a model is not able enough to
capture daily changes in clinical stages, which are out-
comes that can appear repeatedly in a given patient dur-
ing his/her hospital stay. Moreover, the authors found
that growth of Gram-positive cocci and Gram-negative
bacilli in blood increases the risk of progression to severe
sepsis or septic shock during the first 30 days of ICU. In
our study population, in which infections caused by Gram-
negative bacilli were predominant in contradistinction to
other current series across the world [11,31], the type of
microorganism was not associated with progression to
more advanced clinical stages. The apparent “protective
association” of Gram-negative bacilli in blood with first-
week mortality in our cohort is explained by a survival bias,
given by a higher mortality in patients with Gram-negative
bacteremia beginning during the second week. This was
confirmed by the analysis with 28-day mortality, which
showed no association with this type of microorganism
(HR = 1,02; 95% CI = 0,75-1,40).
Dremsizov et al. [9] carried out a study in patients pre-
senting to the emergency room with pneumonia, aimed
at determining the onset and timing of severe sepsis
Table 4 Univariate and multivariate Cox model for 28-day mortality with first-day clinical stage as fixed covariate
Covariables
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (for each year of increase) 1.02 1.01 – 1.02 <0.001 1.01 1.00 – 1.02 <0.001
Sex
Female 1 Reference 1 Reference
Male 1.07 0.90 – 1.28 0.446 1.02 0.84 – 1.23 0.829
Site
Community 1 Reference 1 Reference
Hospital 1.41 1.18 – 1.69 <0.001 1.38 1.10 – 1.72 0.005
Source of infection
Urinary 1 Reference 1 Reference
Respiratory 2.53 1.89 – 3.39 <0.001 1.75 1.25 – 2.45 0.001
Skin and soft tissues 1.13 0.80 – 1.59 0.483 1.30 0.91 – 1.87 0.151
Intra-abdominal 2.20 1.57 – 3.09 <0.001 1.60 1.10 – 2.32 0.013
Other infections 2.03 1.55 – 2.66 <0.001 1.72 1.29 – 2.30 <0.001
Comorbidities
Without comorbidities 1 Reference 1 Reference
With any comorbidity 1.64 1.33 – 2.03 <0.001 1.06 0.84 – 1.33 0.644
SOFA score (0 – 24, for each unit of increase) 1.20 1.18 – 1.23 <0.001 1.08 1.04 – 1.12 <0.001
APACHE II score (0 – 67, for each unit of increase) 1.11 1.09 – 1.12 <0.001 1.05 1.03 – 1.07 <0.001
Blood cultures
Not requested 1 Reference 1 Reference
Negative 1.22 0.99 – 1.50 0.058 1.06 0.84 – 1.32 0.623
Gram-positive bacteria 1.51 1.07 – 2.12 0.018 1.00 0.69 – 1.45 0.980
Gram-negative bacteria 1.55 1.16 – 2.07 0.003 1.02 0.75 – 1.40 0.894
Classification of infection (fixed at admission)
Infection without sepsis 1 Reference 1 Reference
Sepsis 2.08 1.40 – 3.09 <0.001 1.40 0.93 – 2.09 0.105
Severe sepsis 3.23 2.21 – 4.73 <0.001 1.50 0.99 – 2.26 0.052
Septic shock 7.79 5.31 – 11.42 <0.001 2.10 1.33 – 3.32 0.002
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and the ability of the Systemic Inflammatory Response
Syndrome (SIRS) criteria and the Pneumonia Severity
Index (PSI) to predict its development. Of 1339 pa-
tients with pneumonia, 882 did not have severe sepsis
on admission, and 20,6% (n = 182) of these patients
progressed to that stage at some moment of their hospital
stay. The authors found that using 2 or 3 SIRS criteria
does not predict the risk of progression to severe sepsis or
septic shock or 30-day mortality, in contradistinction to
PSI, which was associated with the development of severe
sepsis. Besides considering only a specific type of infection
and a specific type of risk score, that study did not analyze
the factors from the perspective of their change over time,
neither for exposure variables nor for outcome variables.
Glickman et al. [32] carried out an investigation in patients
presenting to the emergency room in order to determine
the incidence, the mortality, and the factors associated with
progression over the first 72 hours from sepsis to septic
shock. The study included 472 patients without shock at
the moment of evaluation in the emergency room, whose
median age was 52 years and median APACHE II score
was 9 points. The most common source of infection in
the whole population was the respiratory, and the fac-
tors associated with progression to septic shock were
catheter-related infection, age, female sex, temperature,
and chronic lung disease. Besides the relative lack of
ability of the logistic regression analysis to explore the
behavior of variables that change over time, the study
might have limitations related with the sample size ne-
cessary for a multivariable analysis.
The strengths of our study include the great diversity
of clinical and epidemiologic aspects of its population, the
quality of the data and the reproducibility of the definitions.
Our study showed that severity scores not only increase
with higher complexity of the infection [24-26] and predict
mortality or organ dysfunction [13,14], which is what
they were designed for, but also determine the risk of
progression to more severe clinical stages. The latter
suggest an additional advantage of severity scores, as
potential tools for exploring the complexity of sepsis
physiopathology. The limitations of our study include
the lack of assessment of the impact of adequate treatment
and resuscitation strategies on progression from one
clinical stage to another [33,34], and the absence of
biochemical markers used in clinical practice such as
C-reactive protein, procalcitonin, or lactate.
Conclusions
This study showed that source of infection, independent
of the initial values of severity scores, increase the risk of
progression to more severe stages of sepsis, and that there
is a differential effect on first-week mortality according
with those stages and their progression. Further studies
are required to validate these conclusions and to identify
interventions capable of modifying risk factors for pro-
gression as well as the mortality outcome in patients with
severe infections that require management in hospital.
Key messages
 The source of infection increase the risk of
progression to more severe stages of sepsis.
 Intraabdominal and respiratory sources of infection,
independently of SOFA and APACHE II scores,
increase the risk of clinical progression to more
severe stages of sepsis.
 There is a differential effect on first-week mortality
according with those stages and their progression.
 Further studies are required to validate these
conclusions.
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